FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

March 6, 2025

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, supported by Deciphera Pharmaceuticals, we had the pleasure of speaking with William D. Tap, MD, about the FDA approval of vimseltinib (Romvimza) for the treatment of patients with symptomatic tenosynovial giant cell tumor (TGCT) for whom surgical resection may worsen functional limitation or cause severe morbidity. Dr Tap is chief of the Sarcoma Medical Oncology Service at Memorial Sloan Kettering Cancer Center in New York, New York.

In our exclusive interview, Dr Tap discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 MOTION trial (NCT05059262), and the increasingly important role that multidisciplinary collaboration will play as this targeted therapy is further integrated into clinical practice.

That’s all we have for today! Thank you for listening to this episode of OncLive On Air, supported by Deciphera Pharmaceuticals. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.